NCT03588741 - Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

June 19, 2019

Study Completion Date

June 19, 2019

Conditions

Haemophilia A

Interventions

DRUG

Turoctocog alfa

"Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month."

Trial Locations (14)

1090

Novo Nordisk Investigational Site, Vienna

1527

Novo Nordisk Investigational Site, Sofia

10249

Novo Nordisk Investigational Site, Berlin

11000

Novo Nordisk Investigational Site, Belgrade

11070

Novo Nordisk Investigational Site, Belgrade

18000

Novo Nordisk Investigational Site, Niš

21000

Novo Nordisk Investigational Site, Novi Sad

35100

Novo Nordisk Investigational Site, Bornova-IZMIR

44093

Novo Nordisk Investigational Site, Nantes

47051

Novo Nordisk Investigational Site, Duisburg

66421

Novo Nordisk Investigational Site, Homburg

NW3 2QG

Novo Nordisk Investigational Site, London

OX3 7LJ

Novo Nordisk Investigational Site, Oxford

S10 2JF

Novo Nordisk Investigational Site, Sheffield